MARKET

NGNE

NGNE

Neurogene
NASDAQ
38.28
-1.18
-2.98%
Opening 09:56 07/16 EDT
OPEN
39.22
PREV CLOSE
39.45
HIGH
39.58
LOW
38.01
VOLUME
12.69K
TURNOVER
--
52 WEEK HIGH
43.66
52 WEEK LOW
15.93
MARKET CAP
755.58M
P/E (TTM)
-8.4263
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at NGNE last week (0706-0710)?
Weekly Report · 3d ago
Neurogene (NGNE) Receives a Buy from LifeSci Capital
TipRanks · 5d ago
Short Report: Ondas bearish bets at record highs
TipRanks · 5d ago
Neurogene President, CFO Christine Mikail Cvijic sells 4,800 shares for $173,468.40
PUBT · 07/08 01:09
Patrick Dolezal Raises Price Target to $65 and Reiterates Buy on NGN-401’s Differentiated Profile and Strong Embolden Study Design
TipRanks · 07/07 15:45
Neurogene grants inducement stock options for 96,450 shares to new employees
PUBT · 07/06 20:01
NEUROGENE ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 07/06 20:01
Weekly Report: what happened at NGNE last week (0629-0703)?
Weekly Report · 07/06 09:01
More
About NGNE
Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.

Webull offers Neurogene Inc stock information, including NASDAQ: NGNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NGNE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NGNE stock methods without spending real money on the virtual paper trading platform.